Potential of Proton Therapy Confirmed for Lung Cancer with Idiopathic Pulmonary Fibrosis
Samsung Medical Center Study Analyzes 41 Patients
Severe Pulmonary Toxicity Rate of 9.4% in Early-Stage Lung Cancer
"Cautious Approach Needed for Stage III or Higher and Severe Pulmonary Fibrosis Patients"
A new study shows that proton therapy may become a new treatment option for lung cancer patients with idiopathic pulmonary fibrosis (IPF), who previously faced difficulties receiving radiation therapy. Particularly in early-stage lung cancer, the incidence rate of severe pulmonary toxicity was found to be less than 10%, confirming the potential for attempting definitive treatment safely. However, for patients with stage III or higher lung cancer or those with severe idiopathic pulmonary fibrosis, the risk of severe pulmonary toxicity remains high and requires caution.
Samsung Medical Center announced on the 19th that the research team, including Professors Pyo Hongryul, Noh Jaemyung, Yang Kyoungmi, and Shin Hyunju from the Department of Radiation Oncology, prospectively evaluated the safety and treatment outcomes of proton therapy in non-small cell lung cancer patients with idiopathic pulmonary fibrosis and reached these conclusions. The study was published in the latest issue of the international journal 'Clinical and Translational Radiation Oncology'.
Medical staff at Samsung Medical Center are preparing for proton therapy. Samsung Medical Center
View original imageIdiopathic pulmonary fibrosis is a chronic disease in which the lung tissue gradually becomes stiff for unknown reasons. Although the risk of developing lung cancer is higher than in the general population, decreased lung function and increased susceptibility to radiation make lung cancer treatment challenging. In conventional X-ray radiation therapy, the incidence rate of severe pulmonary toxicity has been reported to be 20–50%, making aggressive treatment difficult in many cases.
The research team analyzed 41 patients with non-small cell lung cancer and idiopathic pulmonary fibrosis, treated from June 2020 to August 2023. The median patient age was 70 years, and the lung diffusing capacity (DLCO) was about 45% of normal, indicating the cohort was a high-risk group with significantly reduced lung function.
Among 32 patients with early-stage lung cancer, proton therapy was performed relatively safely. Severe pulmonary toxicity of grade 3 or higher developed in 3 patients (9.4%). This is lower than the reported 20–50% severe pulmonary toxicity rate seen with conventional X-ray radiation therapy.
The treatment outcomes were also favorable. The one-year overall survival rate for early-stage lung cancer patients was 80.6%, while the one-year local tumor control rate for all patients was 93.2%.
The research team analyzed that the physical properties of proton therapy contributed to reducing radiation exposure to normal lung tissue. Protons have a ‘Bragg peak’ property, which allows energy to be concentrated at a specific depth, resulting in a sharp decline in radiation dose beyond the tumor. This feature is thought to enhance treatment safety for idiopathic pulmonary fibrosis patients whose lung function is compromised.
Professor Noh stated, “Lung cancer with idiopathic pulmonary fibrosis has always been a challenging area to treat, putting these patients in a blind spot in care. This study provides evidence that, for early-stage patients, a curative attempt using proton therapy can be safely made, and also establishes criteria for identifying which patients require more cautious approaches.”
Professor Pyo commented, “For patients with idiopathic pulmonary fibrosis, radiation therapy has always involved risks. If we establish individualized treatment strategies that consider both cancer stage and the severity of idiopathic pulmonary fibrosis, more patients will have access to treatment opportunities.”
Research team that produced results on the application of proton therapy for lung cancer accompanied by idiopathic pulmonary fibrosis. Samsung Seoul Hospital
View original imageHowever, in progressive lung cancer, a cautious approach to proton therapy is warranted. Severe pulmonary toxicity occurred in 4 out of 9 stage III lung cancer patients (44.4%). Particularly, in the patient group with severe idiopathic pulmonary fibrosis (GAP stage 2 or 3) and stage III lung cancer, the severe pulmonary toxicity rate increased to 57.1%. For patients who also received chemotherapy, the incidence of severe pulmonary toxicity was 50%, higher than the 6.5% in patients who received only radiation therapy.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
The research team suggested that, for patients at high risk of pulmonary toxicity, multidisciplinary discussions are needed to consider alternative strategies, such as palliative radiation or chemotherapy alone. Moving forward, they plan to establish more detailed patient-specific criteria for proton therapy, taking into account both lung cancer stage and idiopathic pulmonary fibrosis severity, through additional patient enrollment and follow-up research.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.